Detalhe da pesquisa
1.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Eur J Haematol
; 107(6): 617-623, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34418168
2.
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.
Haematologica
; 102(8): 1361-1367, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522574
3.
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Eur J Haematol
; 94(3): 243-50, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25082346
4.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 781-787, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278960
5.
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 925, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418611